Evolus EOLS Stock
12.09 USD
{{ price }}
-4.728128%
{{change_pct}}%
SECTOR
Healthcare
COUNTRY
United States
Exchange
NasdaqGM
Market Cap
743.51M USD
LOW - HIGH [24H]
11.97
-
12.61 USD
VOLUME [24H]
321.7K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.08 USD
Evolus Price Chart
Evolus EOLS Financial and Trading Overview
| Evolus stock price | 12.09 USD |
| Previous Close | 7.74 USD |
| Open | 7.74 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 7.57 - 7.8 USD |
| 52 Week Range | 6.51 - 14.29 USD |
| Volume | 676.33K USD |
| Avg. Volume | 505.27K USD |
| Market Cap | 437.74M USD |
| Beta (5Y Monthly) | 1.638732 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.08 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.78 USD |
EOLS Valuation Measures
| Enterprise Value | 483.44M USD |
| Trailing P/E | N/A |
| Forward P/E | -32.041668 |
| PEG Ratio (5 yr expected) | -0.81 |
| Price/Sales (ttm) | 2.798307 |
| Price/Book (mrq) | 63.032787 |
| Enterprise Value/Revenue | 3.09 |
| Enterprise Value/EBITDA | -9.701 |
Trading Information
Evolus Stock Price History
| Beta (5Y Monthly) | 1.638732 |
| 52-Week Change | -33.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 14.29 USD |
| 52 Week Low | 6.51 USD |
| 50-Day Moving Average | 8.83 USD |
| 200-Day Moving Average | 8.61 USD |
EOLS Share Statistics
| Avg. Volume (3 month) | 505.27K USD |
| Avg. Daily Volume (10-Days) | 824.2K USD |
| Shares Outstanding | 56.92M |
| Float | 36.81M |
| Short Ratio | 5.29 |
| % Held by Insiders | 24.04% |
| % Held by Institutions | 58.11% |
| Shares Short | 2.81M |
| Short % of Float | 5.01% |
| Short % of Shares Outstanding | 4.93% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -45.83% |
| Operating Margin (ttm) | -34.41% |
| Gross Margin | 64.95% |
| EBITDA Margin | -31.85% |
Management Effectiveness
| Return on Assets (ttm) | -17.66% |
| Return on Equity (ttm) | -193.27% |
Income Statement
| Revenue (ttm) | 156.43M USD |
| Revenue Per Share (ttm) | 2.78 USD |
| Quarterly Revenue Growth (yoy) | 23.00% |
| Gross Profit (ttm) | 92.73M USD |
| EBITDA | -49833000 USD |
| Net Income Avi to Common (ttm) | -71702000 USD |
| Diluted EPS (ttm) | -1.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 31.46M USD |
| Total Cash Per Share (mrq) | 0.55 USD |
| Total Debt (mrq) | 74.32M USD |
| Total Debt/Equity (mrq) | 1069.51 USD |
| Current Ratio (mrq) | 2.067 |
| Book Value Per Share (mrq) | 0.122 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -67300000 USD |
| Levered Free Cash Flow (ttm) | -42336624 USD |
Profile of Evolus
| Country | United States |
| State | CA |
| City | Newport Beach |
| Address | 520 Newport Center Drive |
| ZIP | 92660 |
| Phone | 949 284 4555 |
| Website | https://www.evolus.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 224 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It serves self-pay aesthetic healthcare market. Evolus, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Q&A For Evolus Stock
What is a current EOLS stock price?
Evolus EOLS stock price today per share is 12.09 USD.
How to purchase Evolus stock?
You can buy EOLS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Evolus?
The stock symbol or ticker of Evolus is EOLS.
Which industry does the Evolus company belong to?
The Evolus industry is Drug Manufacturers-Specialty & Generic.
How many shares does Evolus have in circulation?
The max supply of Evolus shares is 61.5M.
What is Evolus Price to Earnings Ratio (PE Ratio)?
Evolus PE Ratio is now.
What was Evolus earnings per share over the trailing 12 months (TTM)?
Evolus EPS is -1.08 USD over the trailing 12 months.
Which sector does the Evolus company belong to?
The Evolus sector is Healthcare.
Evolus EOLS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}